Management of ascites in patients with liver cirrhosis: Recent evidence and controversies

Journal of the Chinese Medical Association

Volumn 76, Issue 3, 2013, Pages 123-130

  Hsu, Shao Jung ^a   Huang, Hui Chun ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Ascites; Liver cirrhosis; Portal hypertension

Indexed keywords

ADRENALIN; ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; MIDODRINE; OCTREOTIDE; PROPRANOLOL; SATAVAPTAN; SODIUM; TERLIPRESSIN; WATER;

ASCITES; BACTERIAL PERITONITIS; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; ESCHERICHIA COLI; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KLEBSIELLA PNEUMONIAE; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NONHUMAN; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ASCITES; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LYPRESSIN; MIDODRINE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROPRANOLOL;

EID: 84875262227     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.11.005     Document Type: Review

References (62)

1. Runyon B.A., Montano A.A., Akriviadis E.A., Antillon M.R., Irving M.A., McHutchison J.G. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992, 117:215-220.
2. Ginés P., Quintero E., Arroyo V., Terés J., Bruguera M., Rimola A., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7:122-128.
3. Planas R., Montoliu S., Ballesté B., Rivera M., Miquel M., Masnou H., et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006, 4:1385-1394.
4. Lee F.Y., Colombato L.A., Albillos A., Groszmann R.J. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993, 105:1464-1470.
5. Chang C.C., Huang H.C., Wang S.S., Lee F.Y., Chang F.Y., Lin H.C., et al. Involvement of constitutive nitric oxide synthase in the portal-systemic collaterals of portal hypertensive rats. J Chin Med Assoc 2005, 68:245-249.
6. Iwakiri Y., Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006, 43(2 Suppl 1):S121-S131.
7. Runyon B.A., Van Epps D.E. Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peritonitis. Hepatology 1986, 6:396-399.
8. Moore K.P., Wong F., Gines P., Bernardi M., Ochs A., Salerno F., et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003, 38:258-266.
9. Stanley M.M., Ochi S., Lee K.K., Nemchausky B.A., Greenlee H.B., Allen J.I., et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989, 321:1632-1638.
10. Runyon B.A. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986, 146:2259-2261.
11. Deltenre P., Mathurin P., Dharancy S., Moreau R., Bulois P., Henrion J., et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005, 25:349-356.
12. D'Amico G., Luca A., Morabito A., Miraglia R., D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005, 129:1282-1293.
13. Salerno F., Cammà C., Enea M., Rössle M., Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007, 133:825-834.
14. Solà R., Vila M.C., Andreu M., Oliver M.I., Coll S., Gana J., et al. Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. J Hepatol 1994, 20:282-288.
15. Ginès P., Titó L., Arroyo V., Planas R., Panés J., Viver J., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94:1493-1502.
16. Ginès A., Fernández-Esparrach G., Monescillo A., Vila C., Domènech E., Abecasis R., et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996, 111:1002-1010.
17. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417.
18. Wong C.L., Holroyd-Leduc J., Thorpe K.E., Straus S.E. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA 2008, 299:1166-1178.
19. Bernardi M., Caraceni P., Navickis R.J., Wilkes M.M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012, 55:1172-1181.
20. Moreau R., Asselah T., Condat B., de Kerguenec C., Pessione F., Bernard B., et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002, 50:90-94.
21. Singh V., Kumar B., Nain C.K., Singh B., Sharma N., Bhalla A., et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006, 260:62-68.
22. Singh V., Kumar R., Nain C.K., Singh B., Sharma A.K. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006, 21(1 Pt 2):303-307.
23. Appenrodt B., Wolf A., Grünhage F., Trebicka J., Schepke M., Rabe C., et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008, 28:1019-1025.
24. Singh V., Dheerendra P.C., Singh B., Nain C.K., Chawla D., Sharma N., et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008, 103:1399-1405.
25. Alessandria C., Elia C., Mezzabotta L., Risso A., Andrealli A., Spandre M., et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis 2011, 43:881-886.
26. Chan C.C., Lee F.Y., Wang S.S., Chang F.Y., Lin H.C., Chu C.J., et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999, 30:630-635.
27. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107. AASLD Practice Guidelines Committee.
28. Krag A., Møller S., Henriksen J.H., Holstein-Rathlou N.H., Larsen F.S., Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007, 46:1863-1871.
29. Narahara Y., Kanazawa H., Taki Y., Kimura Y., Atsukawa M., Katakura T., et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009, 24:1791-1797.
30. Fimiani B., Guardia D.D., Puoti C., D'Adamo G., Cioffi O., Pagano A., et al. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. Eur J Intern Med 2011, 22:587-590.
31. Schrier R.W., Gross P., Gheorghiade M., Berl T., Verbalis J.G., Czerwiec F.S., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
32. Gerbes A.L., Gülberg V., Ginès P., Decaux G., Gross P., Gandjini H., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.
33. Ginès P., Wong F., Watson H., Terg R., Bruha R., Zarski J.P., et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia-a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010, 31:834-845.
34. Ginès P., Wong F., Watson H., Milutinovic S., del Arbol L.R., Olteanu D., et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008, 48:204-213.
35. Wong F., Watson H., Gerbes A., Vilstrup H., Badalamenti S., Bernardi M., et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012, 61:108-116.
36. Werling K., Chalasani N. What is the role of midodrine in patients with decompensated cirrhosis?. Gastroenterol Hepatol (N Y) 2011, 7:134-136.
37. Angeli P., Volpin R., Piovan D., Bortoluzzi A., Craighero R., Bottaro S., et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998, 28:937-943.
38. Singh V., Dhungana S.P., Singh B., Vijayverghia R., Nain C.K., Sharma N., et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012, 56:348-354.
39. Lebrec D., Poynard T., Hillon P., Benhamou J.P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 1981, 305:1371-1374.
40. Feu F., García-Pagán J.C., Bosch J., Luca A., Terés J., Escorsell A., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995, 346:1056-1059.
41. Wang H.M., Lo G.H., Chen W.C., Tsai W.L., Chan H.H., Cheng L.C., et al. Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients. J Chin Med Assoc 2006, 69:453-460.
42. Abraldes J.G., Tarantino I., Turnes J., Garcia-Pagan J.C., Rodés J., Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003, 37:902-908.
43. Sersté T., Melot C., Francoz C., Durand F., Rautou P.E., Valla D., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010, 52:1017-1022.
44. Wong F., Salerno F. Beta-blockers in cirrhosis: friend and foe?. Hepatology 2010, 52:811-813.
45. Sersté T., Francoz C., Durand F., Rautou P.E., Melot C., Valla D., et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011, 55:794-799.
46. Hernández-Gea V., Aracil C., Colomo A., Garupera I., Poca M., Torras X., et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol 2012, 107:418-427.
47. Soriano G., Guarner C., Tomás A., Villanueva C., Torras X., González D., et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992, 103:1267-1272.
48. Blaise M., Pateron D., Trinchet J.C., Levacher S., Beaugrand M., Pourriat J.L. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994, 20(1 Pt 1):34-38.
49. Fernández J., Ruiz del Arbol L., Gómez C., Durandez R., Serradilla R., Guarner C., et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006, 131:1049-1056.
50. Terg R., Llano K., Cobas S.M., Brotto C., Barrios A., Levi D., et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol 1998, 29:437-442.
51. Ginés P., Rimola A., Planas R., Vargas V., Marco F., Almela M., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990, 12(4 Pt 1):716-724.
52. Singh N., Gayowski T., Yu V.L., Wagener M.M. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995, 122:595-598.
53. Angeli P., Guarda S., Fasolato S., Miola E., Craighero R., Piccolo F., et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006, 23:75-84.
54. Akriviadis E.A., McHutchison J.G., Runyon B.A. Follow-up paracentesis is not usually necessary in patients with typical spontaneous ascitic fluid infection [Abstract]. Hepatology 1997, 26:288A.
55. Arroyo V., Guevara M., Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002, 122:1658-1676.
56. Sort P., Navasa M., Arroyo V., Aldeguer X., Planas R., Ruiz-del-Arbol L., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
57. Sanyal A.J., Boyer T., Garcia-Tsao G., Regenstein F., Rossaro L., Appenrodt B., et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008, 134:1360-1368.
58. Martín-Llahí M., Pépin M.N., Guevara M., Díaz F., Torre A., Monescillo A., et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359.
59. Iwatsuki S., Popovtzer M.M., Corman J.L., Ishikawa M., Putnam C.W., Katz F.H., et al. Recovery from " hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med 1973, 289:1155-1159.
60. Cardenas A., Kelleher T., Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004, 20:271-279.
61. Orman E.S., Lok A.S. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009, 3:582-586.
62. Dhanasekaran R., West J.K., Gonzales P.C., Subramanian R., Parekh S., Spivey J.R., et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol 2010, 105:635-641.